Baystate Medical Center, Inc.

Baystate Medical Center, Inc. acts as a federal grant recipient and subcontractor, delivering clinical research and public health services to federal agencies, with a primary footprint in National Institutes of Health and HHS behavioral health and substance use disorder research programs. Baystate is a tax-exempt, non-profit hospital organization headquartered in Springfield, Massachusetts (759 Chestnut Street), operating as a child entity within a larger Baystate Medical Center parent structure that also does business as Brightwood Health Center.

Baystate's federal work concentrates on clinical research, workforce development, and direct service delivery in addiction medicine, behavioral health, cardiovascular and pulmonary rehabilitation, and child advocacy. The organization functions predominantly as a subcontractor to academic medical centers and research institutions (57% of recent awards) rather than as a prime grant recipient (43%), though it carries a meaningful portfolio of direct SAMHSA, NIH, and Department of Justice awards. Representative prime grant work includes a $599,999 SAMHSA Projects of Regional and National Significance award (CFDA 93.532) issued September 2026 to establish and operate the Child Advocacy Training and Support (CATS) Center, delivering training, consultation, and technical assistance to the 900-member national Children's Advocacy Center network through September 2031; a $905,970 National Institute on Drug Abuse grant (CFDA 93.279) awarded September 2025 for development and testing of the Relational Health Enhanced Parenting Support (RHEP) implementation strategy bundle, working with peer recovery support specialists and the Massachusetts Department of Public Health; and a $900,000 Department of Justice grant (CFDA 16.320) awarded October 2024 for "One Mission: A Comprehensive Service Program for Victims of Human Trafficking," providing trauma-informed screening, case management, and therapeutic services to trafficking victims across a three-year period.

Customer concentration is heavily weighted to federal research and public health agencies. The top five funding sources by award count—the National Heart Lung and Blood Institute (22 awards), the National Institute on Drug Abuse (15 awards), the Substance Abuse and Mental Health Services Administration (12 awards), the Department of Justice's Victims of Crime program (9 awards), and FEMA (6 awards)—account for 60% of recent awards. These rankings reflect Baystate's research mission alignment: most dollar value and award volume anchor in NIH research programs spanning cardiovascular rehabilitation, pulmonary disease, behavioral health interventions, and implementation science, with a secondary concentration in SAMHSA service-delivery and training grants and DOJ victim services funding.

Baystate's subcontractor posture surfaces across its grant portfolio. Named prime grantees routing sub-awards to Baystate include Georgia State University Research Foundation Inc. (repeated consulting and training scope on child sex and labor trafficking, delivered by Dr. Jessica Wozniak), the University of Massachusetts and its medical school (multiple health services research and clinical trial enrollment subcontracts, with Dr. Peter Lindenauer providing analytical and study-oversight leadership), Icahn School of Medicine at Mount Sinai (home-based pulmonary rehabilitation coaching development and implementation), Brigham and Women's Hospital (cardiovascular outcomes research), Yale University (qualitative research and process mapping on medication for opioid use disorder initiation barriers), and Cleveland Clinic (enrolling-site participation in comparative effectiveness trials). Baystate also holds a subcontract from Vanderbilt University Medical Center on a respiratory virus surveillance award (July 2024). The organization's sub-engagement reflects a research-intensive operational model: rather than building internal research infrastructure for every initiative, Baystate typically enrolls patients, provides clinical and implementation oversight, and contributes subject-matter expertise through physician leadership and biostatistical teams housed within its Institute for Healthcare Delivery and Population Science.

Activity has grown substantially: 11 awards in 2022 to 27 in 2024, though 2025 and 2026 show modulation (19 and 7 awards respectively in partial-year data through September 2026). Eight awards reach ultimate completion within the next twenty-four months, representing a modest near-term recompete exposure. Combined obligated dollars across the 106-award footprint total $153.8 million. Service Contract Inventory reporting is minimal—only three SCI records spanning FY2022–FY2024, all as named subcontractors, with 2.1 FTEs in FY2022 and 2.0 FTEs in FY2024—reflecting that Baystate's federal activity is dominated by grant work (which SCI does not capture) and research contracts that fall below the $150,000 SCI threshold or are structured as sub-awards rather than prime service contracts. Accordingly, SCI figures do not represent Baystate's total federal engagement or clinical workforce scale.